Literature DB >> 6858644

Clindamycin and sulphonamides in the treatment of ocular toxoplasmosis.

H Guldsten.   

Abstract

Eight patients with active toxoplasmic retinochoroiditis were treated with clindamycin and a triple sulphonamide combination for a period of up to 6 weeks. In addition systemic prednisone was administered when the optic nerve or the macula was involved (6 of the 8 cases). In all cases we observed clinical improvement within 2 weeks. Visual acuity improved in all cases. Side effects of the treatment were observed in 2 cases. The follow-up period ranged from 8 to 22 months.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6858644     DOI： 10.1111/j.1755-3768.1983.tb01394.x

Source DB:  PubMed          Journal:  Acta Ophthalmol (Copenh)        ISSN： 0001-639X


  11 in total

1.  Paradoxical effect of clindamycin in experimental, acute toxoplasmosis in cats.

Authors:  M G Davidson; M R Lappin; J R Rottman; M B Tompkins; R V English; A T Bruce; J Jayawickrama
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

2.  Clinical manifestation and prognosis of active ocular toxoplasmosis in Iran.

Authors:  Farzan Kianersi; Afsaneh Naderi Beni; Zahra Naderi Beni
Journal:  Int Ophthalmol       Date:  2012-06-26       Impact factor: 2.031

3.  Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial.

Authors:  Nader Baharivand; Ali Mahdavifard; Rohollah Fadaei Fouladi
Journal:  Int Ophthalmol       Date:  2012-09-28       Impact factor: 2.031

4.  Retinal vascular involvement in acute toxoplasmic retinochoroiditis.

Authors:  P Theodossiadis; S Kokolakis; I Ladas; A C Kollia; D Chatzoulis; G Theodossiadis
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

Review 5.  Ocular involvement in toxoplasmosis.

Authors:  A Rothova
Journal:  Br J Ophthalmol       Date:  1993-06       Impact factor: 4.638

6.  Safety of intravitreal clindamycin in albino rabbit eyes.

Authors:  Zohar Habot-Wilner; Orit Mazza; Jonathan Shahar; Amir Massarweh; Irit Mann; Anat Loewenstein; Ido Perlman
Journal:  Doc Ophthalmol       Date:  2017-07-25       Impact factor: 2.379

Review 7.  Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Authors:  Smitha Jasper; Satyanarayana S Vedula; Sheeja S John; Saban Horo; Yasir J Sepah; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2017-01-26

8.  Therapy of ocular toxoplasmosis.

Authors:  A Rothova; H J Buitenhuis; C Meenken; G S Baarsma; T N Boen-Tan; P T de Jong; C M Schweitzer; Z Timmerman; J de Vries; M J Zaal
Journal:  Int Ophthalmol       Date:  1989-12       Impact factor: 2.031

Review 9.  Corticosteroids as adjuvant therapy for ocular toxoplasmosis.

Authors:  Smitha Jasper; Satyanarayana S Vedula; Sheeja S John; Saban Horo; Yasir J Sepah; Quan Dong Nguyen
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

Review 10.  Management of toxoplasmosis.

Authors:  V S Georgiev
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.